Search results
Results from the WOW.Com Content Network
For metastatic renal cell carcinoma, factors which may present a poor prognosis include a low Karnofsky performance-status score (a standard way of measuring functional impairment in patients with cancer), a low haemoglobin level, a high level of serum lactate dehydrogenase, and a high corrected level of serum calcium.
This is an accepted version of this page This is the latest accepted revision, reviewed on 21 February 2025. Medical condition Kidney cancer Other names Renal cancer Micrograph showing the most common type of kidney cancer (clear cell renal cell carcinoma). H&E stain. Specialty Oncology nephrology Urology Symptoms Blood in the urine, lump in the abdomen, back pain Usual onset After the age of ...
This is a shortened version of the second chapter of the ICD-9: Neoplasms.It covers ICD codes 140 to 239.The full chapter can be found on pages 101 to 144 of Volume 1, which contains all (sub)categories of the ICD-9.
Metastasis is a pathogenic agent's spreading from an initial or primary site to a different or secondary site within the host's body; [1] the term is typically used when referring to metastasis by a cancerous tumor. [2] The newly pathological sites, then, are metastases (mets).
The most frequent, malignant, primary kidney cancer is renal cell carcinoma (RCC) - which has several subtypes: Clear cell RCC, an epithelial cell tumour of the kidney that accounts for 65-70% of all RCCs. [5] Papillary RCC, a renal tumour that accounts for 10-15% of all RCCs. Males are 1.5 times as likely to develop this type of tumour than ...
M8315/3 Glycogen-rich carcinoma; M8316/3 Cyst-associated renal cell carcinoma (C64.9) M8317/3 Renal cell carcinoma, chromophobe type (C64.9) Chromophobe cell renal carcinoma; M8318/3 Renal cell carcinoma, sarcomatoid (C64.9) Renal cell carcinoma, spindle cell; M8319/3 collecting duct carcinoma (C64.9) Bellini duct carcinoma; Renal carcinoma ...
Tumor markers may be used for the following purposes: Monitoring the malignancy; When a malignant tumor is found by the presence of a tumor marker, the level of marker found in the body can be monitored to determine the state of the tumor and how it responds to treatment.
Papillary renal cell carcinoma (PRCC) is a malignant, heterogeneous tumor originating from renal tubular epithelial cells of the kidney, which comprises approximately 10-15% of all kidney neoplasms. [1] Based on its morphological features, PRCC can be classified into two main subtypes, which are type 1 and type 2 (eosinophilic). [2]